EZ Cap™ Mouse IL-36γ mRNA (m1Ψ, HA tag)

Il-36γ is a cytokine in the interleukin-36 (IL-36) family that is mainly involved in inflammatory response and immune regulation. IL-36γ is produced mainly by epithelial cells, keratinocytes, and certain immune cells such as dendritic cells and macrophages. Il-36γ activates downstream signaling pathways, such as the NF-κB and MAPK pathways, by binding to IL-36 receptors, thereby promoting the release of inflammatory factors and the activation of immune cells.

IL-36γ plays a role in a variety of inflammatory diseases, including psoriasis, inflammatory bowel disease, and rheumatoid arthritis. Studies have shown that IL-36γ may have a pro-inflammatory role in the pathological process of these diseases, and thus become a potential therapeutic target. Because of its importance in modulating the immune response, IL-36γ is also thought to have a potential protective effect in anti-infection immunity.

EZ Cap™ Mouse IL-36γ mRNA (m1Ψ, HA tag) is provided at a concentration of ~1 mg/ml with Cap1 structure. It expresses Mouse IL-36γ cytokine with HA label, which is convenient for the subsequent detection of protein expression. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of N1-Methylpseudo-UTP(m1Ψ) and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.